Scholar Rock Holding Corp
SRRK44.050USD
+0.430+0.99%
Cierre 12/31, 16:00（ET）Cotizaciones retrasadas 15 min
4.37BCap. mercado
PérdidaP/E TTM
Más Datos de Scholar Rock Holding Corp Compañía
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Información de Scholar Rock Holding Corp
Símbolo de cotizaciónSRRK
Nombre de la empresaScholar Rock Holding Corp
Fecha de salida a bolsaMay 24, 2018
Director ejecutivoHallal (David L)
Número de empleados196
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 24
Dirección301 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono18572593860
Sitio Webhttps://scholarrock.com/
Símbolo de cotizaciónSRRK
Fecha de salida a bolsaMay 24, 2018
Director ejecutivoHallal (David L)
Ejecutivos de Scholar Rock Holding Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David L. Hallal
Mr. David L. Hallal
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.60M
-11.36%
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
President - Research & Development, Director
President - Research & Development, Director
616.21K
-1.08%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Chief Financial Officer
Chief Financial Officer
600.00K
--
Ms. Caryn Parlavecchio
Ms. Caryn Parlavecchio
Chief Human Resources Officer
Chief Human Resources Officer
155.46K
-1.38%
Ms. Junlin Ho, J.D.
Ms. Junlin Ho, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
96.29K
+1.19%
Ms. Tracey Sacco
Ms. Tracey Sacco
Chief Commercial Officer
Chief Commercial Officer
22.46K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
21.07K
+11.85%
Ms. Katie Peng
Ms. Katie Peng
Independent Director
Independent Director
18.27K
-5.22%
Dr. Mo Qatanani, Ph.D.
Dr. Mo Qatanani, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.59K
-18.11%
Mr. Joshua Reed
Mr. Joshua Reed
Independent Director
Independent Director
15.73K
+16.53%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David L. Hallal
Mr. David L. Hallal
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.60M
-11.36%
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
President - Research & Development, Director
President - Research & Development, Director
616.21K
-1.08%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Chief Financial Officer
Chief Financial Officer
600.00K
--
Ms. Caryn Parlavecchio
Ms. Caryn Parlavecchio
Chief Human Resources Officer
Chief Human Resources Officer
155.46K
-1.38%
Ms. Junlin Ho, J.D.
Ms. Junlin Ho, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
96.29K
+1.19%
Ms. Tracey Sacco
Ms. Tracey Sacco
Chief Commercial Officer
Chief Commercial Officer
22.46K
--
Desglose de ingresos
FY2024
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
13.69%
Invus Public Equities Advisors, LLC
9.07%
T. Rowe Price Associates, Inc.
6.65%
Samsara BioCapital, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.57%
Otro
59.34%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
13.69%
Invus Public Equities Advisors, LLC
9.07%
T. Rowe Price Associates, Inc.
6.65%
Samsara BioCapital, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.57%
Otro
59.34%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
58.97%
Investment Advisor/Hedge Fund
32.88%
Hedge Fund
12.76%
Venture Capital
9.33%
Individual Investor
3.92%
Research Firm
2.77%
Sovereign Wealth Fund
1.15%
Pension Fund
0.99%
Bank and Trust
0.25%
Participación institucional
Actualizado: hace una hora
Actualizado: hace una hora
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
512
121.53M
119.14%
+2.04M
2025Q3
483
118.67M
123.52%
-2.02M
2025Q2
466
118.81M
123.62%
+4.48M
2025Q1
456
113.90M
119.97%
-666.42K
2024Q4
421
111.65M
118.02%
+13.32M
2024Q3
371
94.78M
117.45%
-2.79M
2024Q2
357
92.97M
115.37%
-3.23M
2024Q1
328
91.48M
116.64%
-131.69K
2023Q4
308
87.39M
122.16%
+15.93M
2023Q3
283
62.18M
111.86%
-162.68K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
13.78M
14.34%
+39.58K
+0.29%
Jun 30, 2025
Invus Public Equities Advisors, LLC
9.25M
9.62%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
8.67M
9.02%
-138.19K
-1.57%
Jun 30, 2025
Samsara BioCapital, LLC
5.61M
5.91%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.70M
5.93%
-329.09K
-5.46%
Jun 30, 2025
The Vanguard Group, Inc.
4.85M
5.04%
+16.39K
+0.34%
Jun 30, 2025
Wellington Management Company, LLP
2.02M
2.11%
+179.87K
+9.75%
Jun 30, 2025
Redmile Group, LLC
3.93M
4.09%
-469.24K
-10.67%
Jun 30, 2025
State Street Investment Management (US)
3.07M
3.2%
-59.84K
-1.91%
Jun 30, 2025
Bellevue Asset Management AG
2.95M
3.07%
+440.40K
+17.57%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
5.43%
Roundhill GLP-1 & Weight Loss ETF
2.04%
State Street SPDR S&P Biotech ETF
1.71%
Amplify Weight Loss Drug & Treatment ETF
1.26%
Tema Heart & Health ETF
0.77%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.6%
First Trust Multi-Manager Small Cap Opportunities ETF
0.59%
AltShares Event-Driven ETF
0.53%
ProShares Ultra Nasdaq Biotechnology
0.52%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción5.43%
Roundhill GLP-1 & Weight Loss ETF
Proporción2.04%
State Street SPDR S&P Biotech ETF
Proporción1.71%
Amplify Weight Loss Drug & Treatment ETF
Proporción1.26%
Tema Heart & Health ETF
Proporción0.77%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.63%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.6%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.59%
AltShares Event-Driven ETF
Proporción0.53%
ProShares Ultra Nasdaq Biotechnology
Proporción0.52%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Scholar Rock Holding Corp?
Los cinco principales accionistas de Scholar Rock Holding Corp son:
Fidelity Management & Research Company LLC posee 13.78M acciones, lo que representa el 14.34% del total de acciones.
Invus Public Equities Advisors, LLC posee 9.25M acciones, lo que representa el 9.62% del total de acciones.
T. Rowe Price Associates, Inc. posee 8.67M acciones, lo que representa el 9.02% del total de acciones.
Samsara BioCapital, LLC posee 5.61M acciones, lo que representa el 5.91% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.70M acciones, lo que representa el 5.93% del total de acciones.
Fidelity Management & Research Company LLC posee 13.78M acciones, lo que representa el 14.34% del total de acciones.
Invus Public Equities Advisors, LLC posee 9.25M acciones, lo que representa el 9.62% del total de acciones.
T. Rowe Price Associates, Inc. posee 8.67M acciones, lo que representa el 9.02% del total de acciones.
Samsara BioCapital, LLC posee 5.61M acciones, lo que representa el 5.91% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.70M acciones, lo que representa el 5.93% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Scholar Rock Holding Corp?
Los tres principales tipos de accionista de Scholar Rock Holding Corp son:
Fidelity Management & Research Company LLC
Invus Public Equities Advisors, LLC
T. Rowe Price Associates, Inc.
Fidelity Management & Research Company LLC
Invus Public Equities Advisors, LLC
T. Rowe Price Associates, Inc.
¿Cuántas instituciones poseen acciones de Scholar Rock Holding Corp (SRRK)?
A fecha de 2025Q4, 512 instituciones poseen acciones de Scholar Rock Holding Corp, con un valor de mercado combinado de aproximadamente 121.53M, lo que representa el 119.14% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -4.38%.
¿Cuál es la mayor fuente de ganancias de Scholar Rock Holding Corp?
El FY2024, el segmento empresarial -- generó la ganancia más alta para Scholar Rock Holding Corp, ascendiendo a -- y representando el --% de la ganancia total.
